Next Phase Newsletter

A venture capital firm backed by a major global financial services group actively invests across multiple sectors, including life sciences. The firm typically invests USD 1–2 million per round, though it is capable of larger allocations depending on the opportunity. While globally active, the firm focuses on opportunities with strong relevance to specific market needs in Asia. 

In the life sciences space, the firm is currently targeting therapeutic and medtech products that address major unmet medical needs in its home market. It favors companies with a clear strategy to collaborate with regional pharmaceutical partners, whether through licensing, co-development, or strategic equity participation. The firm considers a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated drugs. It primarily seeks products in Phase I clinical trials but may also invest in assets within one year of entering the clinic. Indications of strong interest include oncology and orphan diseases. 

The firm only co-invests in opportunities outside of its home country and strongly prefers that a reputable institutional lead or established syndicate be in place before participating. As such, it tends to evaluate international deals with a co-investment mindset alongside other institutional investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This venture capital firm headquartered in Northern Europe, is currently deploying capital from a life science focused fund. The firm primarily invests in biotech and digital health companies based in the Nordic and Baltic regions. The firm participates from Pre-Seed through Series A rounds, typically writing initial checks ranging from €250,000 to €3 million. The firm is open to both leading and co-investing in financing rounds. 

While the firm’s primary focus lies in biotech and digital health, the firm is also open to investing in medical devices and diagnostics. Within biotech, the firm supports companies from the preclinical stage through to Phase I, with Phase II generally considered the latest point of entry. The firm maintains a disease-agnostic approach and is more focused on platform potential and scientific merit than on specific indications. 

In most investments, the firm will seek a board seat, or at minimum, observer rights, reflecting its active involvement and strategic engagement with portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A Europe-based venture capital firm manages a dedicated fund focused on diabetes and related conditions. Its investment sweet spot ranges from Seed to Series A, with typical check sizes between $1–3 million. The firm invests globally and is open to both leading and co-investing. Its team brings strong scientific and industry expertise in the diabetes space and actively supports portfolio companies, including through board and observer roles. 

The firm focuses on diabetes and related indications such as comorbidities or conditions where diabetes is a key driver (e.g., kidney disease, wound care, and vision loss). It primarily invests in medical devices and digital health solutions, avoiding traditional biotech therapeutics. For hardware, the firm seeks technologies beyond the prototype stage with early data (lab, clinical, or first-in-human). For software, it prioritizes products showing commercial traction or scalable business models. For B2B products, validation through partnerships with medtech firms or healthcare systems is a strong advantage. 

There are no specific requirements regarding a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A US-based venture capital firm with a hands-on investment approach and a strong commitment to supporting underrepresented founders  invests at the Seed and Series A stages, typically leading rounds with initial check sizes of up to $2 million in equity. The firm makes approximately 1-3 new investments per year and focuses on companies based in the United States. 

Within life sciences, the firm invests in disruptive technologies in the medical device sector and is open to all classes of medical devices. 

The firm is dedicated to backing diverse founding teams. Its current portfolio includes a significant proportion of companies led by women and minorities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm based in Western Europe invests in healthcare companies with typical check sizes ranging from €1–20 million, usually entering at the second or third round of financing and participating through Series B. The firm focuses on companies based in the U.S. and Europe. 

The firm invests in diagnostics, digital health, and medical devices, but does not invest in drugs, biotech, or therapeutics. The firm targets companies in the in-development or clinical stages and is indication-agnostic. 

The firm does not have specific requirements for management teams and typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm with offices in the US typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity. 
 
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures. 
 
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A U.S. subsidiary of a China-headquartered enterprise focused on advanced manufacturing and technical services, medical and healthcare, trade, and engineering services. The firm is seeking investment opportunities in life sciences and healthcare. The firm is open to various deal structures, including equity investments, M&A, and joint ventures. 
 

For equity investments, the firm’s sweet spots are Series A and Series B, although the firm is capable of making later-stage investments. Typical check sizes range from $10M to $100M. While primarily focused on opportunities in the U.S., the firm is also open to investments in North and South America. 
 
The firm is most interested in biotech therapeutics and pharmaceuticals and remains opportunistic regarding modalities and indications. The firm typically evaluates assets in Phase I or Phase II. Other areas of interest include hospital products, especially those leveraging AI, as well as surgical tools and R&D research technologies. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology